reboxetine has been researched along with olanzapine in 11 studies
| Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (olanzapine) | Trials (olanzapine) | Recent Studies (post-2010) (olanzapine) |
|---|---|---|---|---|---|
| 626 | 193 | 184 | 6,339 | 1,340 | 2,383 |
| Protein | Taxonomy | reboxetine (IC50) | olanzapine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.097 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.155 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.047 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.04 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.541 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.768 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.118 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.047 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.421 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.531 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.392 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.072 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.173 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.092 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.038 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.021 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.047 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 1.033 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.013 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.078 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.057 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.013 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.158 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.2028 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Arnone, D; Hansen, L; Kerr, JS | 1 |
| Faragian, S; Fuchs, C; Isaacs, I; Poyurovsky, M; Schneidman, M; Weizman, A; Weizman, R | 1 |
| Faragian, S; Fuchs, C; Gil-Ad, I; Levi, A; Maayan, R; Pashinian, A; Poyurovsky, M | 1 |
| Bajbouj, M; Danker-Hopfe, H; Gallinat, J; Hellen, F; Lang, UE; Lisanby, SH; Neu, P; Vesper, J | 1 |
| Faragian, S; Fuchs, C; Pashinian, A; Poyurovsky, M | 1 |
| Björkholm, C; Jardemark, K; Malmerfelt, A; Marcus, MM; Svensson, TH | 1 |
| Fisar, Z; Hroudová, J; Raboch, J | 1 |
| Fuchs, C; Levi, A; Pashinian, A; Poyurovsky, M; Weizman, A; Weizman, R | 1 |
| Amrami-Weizman, A; Fuchs, C; Gil-Ad, I; Kotler, M; Maayan, R; Pashinian, A; Poyurovsky, M | 1 |
| Bernardo, M; Caballero, M; Corripio, I; Felipe, AE; Fernandez de Corres, B; González Piqueras, JC; Huerta, R; Ibáñez, A; Iniesta, R; López-Carrilero, R; Oliveira, C; Roca, M; Rodriguez-Jimenez, R; Sindreu, SD; Usall, J | 1 |
| Koziorowski, M; Mytych, J; Sołek, P; Tabęcka-Łonczyńska, A | 1 |
6 trial(s) available for reboxetine and olanzapine
| Article | Year |
|---|---|
Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Morpholines; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Reboxetine; Schizophrenia; Treatment Outcome; Weight Gain | 2003 |
Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Appetite; Benzodiazepines; Body Mass Index; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Olanzapine; Reboxetine; Schizophrenia; Weight Gain | 2007 |
Motor cortex excitability after vagus nerve stimulation in major depression.
Topics: Adult; Benzodiazepines; Citalopram; Clomipramine; Clozapine; Depressive Disorder; Doxepin; Drug Therapy, Combination; Electric Stimulation; Female; Humans; Lamotrigine; Lithium Carbonate; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Motor Cortex; Neural Conduction; Neural Inhibition; Olanzapine; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Tranylcypromine; Triazines; Vagus Nerve; Valproic Acid | 2007 |
Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Benzodiazepines; Betahistine; Double-Blind Method; Female; Histamine Agonists; Humans; Male; Middle Aged; Morpholines; Olanzapine; Reboxetine; Schizophrenia; Treatment Outcome; Weight Gain; Young Adult | 2013 |
The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Morpholines; Olanzapine; Reboxetine; Schizophrenia; Weight Gain; Young Adult | 2013 |
Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Citalopram; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Olanzapine; Psychiatric Status Rating Scales; Reboxetine; Risperidone; Schizophrenia; Schizophrenic Psychology | 2014 |
5 other study(ies) available for reboxetine and olanzapine
| Article | Year |
|---|---|
Acute dystonic reaction in an elderly patient with mood disorder after titration of paroxetine: possible mechanisms and implications for clinical care.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dystonic Disorders; Electroconvulsive Therapy; Humans; Male; Morpholines; Olanzapine; Paroxetine; Pirenzepine; Reboxetine | 2002 |
Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Neuropsychological Tests; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Reboxetine; Schizophrenia; Schizophrenic Psychology; Young Adult | 2009 |
Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Benzodiazepines; Cerebral Cortex; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Excitatory Amino Acid Agonists; Freezing Reaction, Cataleptic; In Vitro Techniques; Male; Membrane Potentials; Microdialysis; Morpholines; N-Methylaspartate; Olanzapine; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reboxetine; Receptors, N-Methyl-D-Aspartate | 2010 |
Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.
Topics: Affect; Amitriptyline; Animals; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Cerebral Cortex; Citalopram; Clorgyline; Cocaine; Cyclohexanols; Desipramine; Fluoxetine; Imipramine; In Vitro Techniques; Iproniazid; Lithium; Mianserin; Mirtazapine; Mitochondria; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Morpholines; Olanzapine; Pargyline; Reboxetine; Swine; Thiazepines; Valproic Acid; Venlafaxine Hydrochloride | 2010 |
Molecular Consequences of Depression Treatment: A Potential In Vitro Mechanism for Antidepressants-Induced Reprotoxic Side Effects.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antipsychotic Agents; Cell Line; Escitalopram; Fluoxetine; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation; Imipramine; Male; Mice; Micronuclei, Chromosome-Defective; Mirtazapine; Models, Biological; Olanzapine; Organ Specificity; Reboxetine; Reproduction; Signal Transduction; Spermatogenesis; Telomeric Repeat Binding Protein 1; Telomeric Repeat Binding Protein 2; Time Factors; Venlafaxine Hydrochloride | 2021 |